To explore the potential mechanism of morin in improving airway inflammation in asthma.

In animal experiments, rats were randomly divided into four groups, with 10 rats in each group: animal control group, animal model group [ovalbumins (OVA)-induced], animal experimental-L group (OVA-induced + 10 mg·kg^-1 morin), animal experimental-M (OVA-induced+30 mg·kg^-1 morin) and the experimental-H group (OVA-induced+100 mg·kg^-1 morin). After 4 weeks of treatment, bronchoalveolar lavage fluid (BALF) and serum were collected for subsequent use, and lung tissues were harvested. Western blot assay was used to detect the expression of murine double minute 2(MDM2) protein; enzyme-linked immunosorbent assay (ELISA) assay was employed to determine the expression of inflammatory factors in BALF; and real-time fluorescence quantitative polymerase chain reaction (RT-qPCR) assay was applied to measure the mRNA expressions of tumor protein 53 (p53) and BCL-2 associated X protein (Bax). In cell experiments, 16HBE cells were randomly assigned to four groups: cell blank group, cell model group [treated with 50 μg·L^-1 interleukin(IL)-13], cell experimental group (treated with 65 μmol·L^-1 morin+IL-13), si-NC group(transfected with si-NC, then treated with 65 μmol·L^-1 morin+IL-13) and si-MDM2 group (transfected with si-MDM2, then treated with 65 μmol·L^-1 morin+IL-13). After 48 hours of treatment, TdT mediated dUDP nick end labeling(Tunel) assay was used to detect the cell apoptosis rate; Western blot assay was performed to determine protein expression and P53 ubiquitination level.

In animal experiments, the levels of MDM2 protein in the animal control group, animal model group, animal experimental-L group, animal experimental-M and animal experimental-H group were 0.65±0.05, 0.32±0.03, 0.41±0.06, 0.46±0.04 and 0.51±0.05, respectively; the levels of BALF-IL-13 were (15.44±1.19), (55.43±3.90), (48.79±4.88), (37.25±4.59) and (25.64±1.64) pg·mL^-1, respectively; the relative expression levels of p53 mRNA were 1.00±0.14, 1.75±0.13, 1.51±0.12, 1.44±0.09 and 1.24±0.14, respectively; the relative expression levels of Bax mRNA were 1.00±0.14, 1.94±0.16, 1.75±0.17, 1.62±0.17 and 1.39±0.09, respectively; when comparing the animal model group with the animal control group, and the animal experimental-L, -M, -H groups with the animal model group respectively, the differences of the above indicators were all statistically significant (P<0.05, P<0.01). In cell experiment, the apoptosis rates of cells in cell blank group, cell model group, cell experimental group, si-NC group and si-MDM2 group were (3.94±0.27), (31.76±2.39), (19.93±1.91), (18.14±2.50) and (25.97±1.74)%, respectively; the realtive expression levels of MDM2 protein were 0.91±0.09, 0.44±0.05, 0.66±0.08, 0.68±0.05 and 0.21±0.04, respectively; when comparing the cell model group with the cell blank group, the cell experimental group with the cell model group, the si-MDM2 group with the si-NC group, the differences of the above indicators were all statistically significant (all P<0.01).

Morin may alleviate asthmatic airway inflammation and cell apoptosis by upregulating MDM2 ubiquitination to regulate p53.

To investigate the potential mechanism of lycopene mediating iron autophagy in improving the inflammatory response in endometriosis (EMs).

Fifty rats were randomly divided into sham group, model group (EMs model was constructed), experiment-L group (10.0 mg·kg^-1 lycopene after modeled), experiment-H group (20.0 mg·kg^-1 lycopene after modeled) and positive group (1.05 mg·kg^-1 mifepristone after modeled), with 10 rats in each group. At the end of drug treatment, the volume of ectopic endometrial tissue were detected, and detected free iron content with a corresponding detection kit. The expressions of vascular endothelial growth factor A (VEGFA), interleukin (IL) -8, nuclear receptor coactivator 4 (NCOA4) and microtubule-associated protein 1 light chain 3B (LC3B) were detected by immunofluorescence, or Western blot.

The volumes of ectopic endometrial lesion tissues in the sham group, the model group, the experiment-L group, the experiment-H group and the positive group of rats were (0.00±0.00), (130.92±12.45), (97.55±10.56), (71.96±6.46), and (54.22±2.72) mm³, respectively; the levels of free iron were (262.89±23.51), (636.97±58.75), (523.63±46.13), (383.30±38.92) and (603.15±69.98) μmol·kg^-1, respectively; the immunofluorescence intensities of VEGFA were (1 034.45±102.39), (3 628.16±104.65), (3 100.73±231.67), (2 193.07±293.16) and (3 418.68±377.98) a.u., respectively; the relative expression levels of IL-8 protein were 0.22±0.05, 0.79±0.10, 0.62±0.10, 0.49±0.06 and 0.71±0.07, respectively; the relative expression levels of NCOA4 protein were 0.33±0.04, 1.12±0.13, 0.85±0.10, 0.61±0.09 and 1.05±0.08, respectively; the relative expression levels of LC3Ⅱ/Ⅰ protein were 0.36±0.04, 1.02±0.12, 0.78±0.08, 0.51±0.05 and 0.94±0.07, respectively. Compared the sham operation group with the model group, compared experiment-L and experiment-H groups with the model group, the differences of above indicators were all statistically significant (all P<0.05).

Lycopene significantly inhibits inflammation and angiogenesis in EMs rats, thereby reducing the volume of ectopic lesions, which may be related to the inhibition of iron autophagy signaling.

To observe the clinical efficacy and safety of allylestrenol tablet combined with ritodrine hydrochloride tablet in the treatment of patients with gestational diabetes mellitus and threatened premature labor.

The patients with gestational diabetes mellitus threatened premature delivery were divided into treatment group and control group according to the treatment method. The control group received conventional treatment+ritodrine hydrochloride injection (100 mg, intravenous drip, continuous infusion after stopping uterine contraction for 12 h)+ritodrine hydrochloride tablets (10 mg, oral, q2 h on the first day, q4 h on the second day, q6 h on the day 3-7); on the basis of control group, the treatment group was added with allylestradiol tablets (5 mg, orally, 3-4 times a day). The course of treatment for both groups was 7 days. The clinical efficacy, blood glucose-related indicators, inflammatory-related indicators, pregnancy outcomes and neonatal outcomes were compared between the two groups, and safety was evaluated.

A total of 98 cases were included in this study, including 50 cases in control group and 48 cases in treatment group. After treatment, the total clinical effective rates in treatment group and control group were 93.75% (45 cases/48 cases) and 80.00% (40 cases/50 cases), respectively, with statistically significant difference (P<0.05). After treatment, the fasting blood glucose (FBG) levels in treatment group and control group were (5.26±0.11) and (5.28±0.17) mmol·L^-1, respectively; the 2-hour postprandial blood glucose (2 h PG) levels were (6.35±0.25) and (6.42±0.24) mmol·L^-1, respectively; interleukin-6 (IL-6) levels were (6.49±1.06) and (7.13±1.43) pg·mL^-1, respectively; IL-8 levels were (12.59±2.17) and (13.94±2.60) pg·mL^-1, respectively; IL-10 levels were (12.30±2.49) and (11.09±1.95) pg·mL^-1, respectively; prolonged pregnancy duration were (11.67±3.84) and (9.82±2.96) days, respectively; the proportions of vaginal delivery was 66.67% (32 cases/48 cases) and 46.00% (23 cases/50 cases), respectively; postpartum blood loss levels were (185.21±21.49) and (196.58±24.75) mL, respectively; the 1-minute Apgar scores of newborns were (9.04±0.20) and (8.86±0.35) points, respectively; the live birth rates were 97.92% (47 cases/48 cases) and 90.00% (45 cases/50 cases), respectively; the incidences of neonatal respiratory distress syndrome (NRDS) were 4.17% (2 cases/48 cases) and 20.00% (10 cases/50 cases), respectively; the incidences of apnea in premature infants were 4.17% (2 cases/48 cases) and 18.00% (9 cases/50 cases), respectively; the incidences of hematosepsis were 6.25% (3 cases/48 cases) and 14.00% (7 cases/50 cases), respectively; the incidences of neonatal pneumonia were 2.08% (1 cases/48 cases) and 6.00% (3 cases/50 cases), respectively. Except for FBG, 2 h PG, live birth rate, incidences of neonatal sepsis and neonatal pneumonia, the differences in the above indicators between treatment group and control group were all statistically significant (P<0.05, P<0.01). The adverse drug reactions in treatment group were primarily palpitations, nausea and vomiting, and headache, while those in control group mainly included palpitations, constipation, nausea and vomiting. The incidences of adverse drug reactions in treatment group and control group were 6.25% (3 cases/48 cases) and 8.00% (4 cases/50 cases), respectively, with no statistically significant difference (P>0.05).

Allylestrenol tablet combined with ritodrine hydrochloride tablet can effectively treat threatened preterm labor in gestational diabetes mellitus, significantly prolong gestational age, improve inflammatory responses, and optimize pregnancy and neonatal outcomes without increasing the risk of adverse drug reactions.

To observe the efficacy of polyethylene glycol recombinant human growth hormone (PEG-rhGH) injection combined with vitamin D drops and lysine hydrochloride and calcium hydrogen phosphate granules in the treatment of children with idiopathic short stature (ISS).

Based on treatment regimen, children with ISS were categorized into treatment and control groups. Both groups received basic treatment of vitamin D drops (400-800 U daily) and lysine hydrochloride and calcium hydrogen phosphate granules (5 g, twice daily). The control group was given human somatropin injection at a dose of 0.10-0.20 IU·kg^-1·d^-1 by subcutaneous injection, while the treatment group was given PEG-rhGH injection at a dose of 0.20-0.40 mg·kg^-1·w^-1 by subcutaneous injection. Both groups received continuous medication for 12 months. The clinical efficacy, evaluation indicators of GH-insulin-like growth factor (IGF) axis function, bone metabolism indicators and safety were compared between the two groups.

The study enrolled 79 cases, comprising 41 cases in the treatment group and 38 cases in the control group. After treatment, the effective rates of the treatment group and the control group were 95.12% (39 cases/41 cases) and 92.11% (35 cases/38 cases), respectively, with no statistically significant difference (P>0.05). After treatment, the levels of insulin-like growth factor-1/insulin-like growth factor binding protein-3 (IGF-1/IGFBP-3) in the treatment group and the control group were 0.08±0.02 and 0.07±0.02, respectively; the levels of liver-expressed antimicrobial peptide-2 (LEAP-2) were (1 395.69±187.26) pg·mL^-1 and (1 487.58±195.48) pg·mL^-1, respectively; the levels of osteocalcin (BGP) were (22.18±3.67) and (20.43±3.48) μg·L^-1, respectively; procollagen I N-terminal peptide (PINP) were (602.68±63.41) and (574.08±61.83) μg·L^-1, respectively; bone-specific alkaline phosphatase (BALP) was (192.68±23.64) and (203.41±22.18) U·L^-1, respectively; vitamin D (Vit-D) were (20.39±3.47) and (18.65±3.62) ng·mL^-1, respectively. Both indicators showed statistically significant differences between the two groups (all P<0.05). The incidences of adverse drug reactions of treatment group and the control group were 7.32% (3 cases/41 cases) and 10.53% (4 cases/38 case), with no statistically significant difference (P>0.05).

PEG-rhGH injection at a dose of 0.20-0.40 mg·kg^-1·w^-1 combined with vitamin D drops and lysine hydrochlodride and calcium hydrogen phosphate granules in the treatment of children with ISS can ensure efficacy and safety, while potentially achieving better long-term growth improvement effects. It can also improve the function of the GH-IGF axis and bone metabolism levels.

To explore the clinical therapeutic effect of inclisiran injection combined with rosuvastatin tablets in the treatment of patients with extremely high-risk atherosclerotic cardiovascular disease (ASCVD).

The patients with extremely high-risk ASCVD were divided into the treatment group and the control group according to the actual clinical medication regimens they received. The control group was given rosuvastatin calcium tablets 10 mg, po, qd, while the treatment group was given inclisiran sodium injection 284 mg, ih, for the first time, and 284 mg, ih, again after 3 months on the basis of control group. The treatment duration for both groups was 6 months. The clinical efficacy, lipid profile, low-density lipoprotein cholesterol (LDL-C) target attainment rate, proprotein convertase subtilisin/kexin type 9 (PCSK9) levels, cardiac function, plaque stability, safety evaluation, and cardiovascular benefits were compared between the two groups.

A total of 98 patients were enrolled, with 51 in the control group and 47 in the treatment group. After treatment, the overall response rates in the control group and the treatment group and were 68.63% (35 cases/51 cases) and 87.23% (41 cases/47 cases), respectively; the LDL-C levels were (1.42±0.27) and (1.26±0.22) mmol·L^-1, respectively; the LDL-C goal attainment rates at 3 months were 41.18% (21 cases/51 cases) and 61.70% (29 cases/47 cases), respectively; LDL-C goal attainment rates at 6 months were 52.94% (27 cases/51 cases) and 74.47% (35 cases/47 cases), respectively; PCSK9 levels at 3 months were (313.66±41.35) and (295.63±39.43) ng·mL^-1, respectively; PCSK9 levels at 6 months were (203.71±33.39) and (184.29±31.54) ng·mL^-1, respectively; carotid intima-media thickness were (1.01±0.27) and (0.91±0.11) mm, respectively; plaque areas were (18.52±3.76) and (16.31±3.63) mm², respectively; proportions of unstable plaques were 39.22% (20 cases/51cases) and 19.15% (9 cases/47 cases), respectively; high-density lipoprotein cholesterol (HDL-C) levels were (1.46±0.55) and (1.47±0.33) mmol·L^-1, respectively; apolipoprotein A (ApoA) levels were (1.11±0.25) and (1.10±0.29) g·L^-1, respectively. Except HDL-C level and ApoA level, comparisons of other indexes between the two groups showed statistically significant differences (P<0.05, P<0.01). No significant difference in the incidence of adverse events was observed between the control group (5.88%, 3 cases/51 cases) and treatment group (8.51%, 4 cases/47 cases) (P>0.05).

The combination of inclisiran injection and rosuvastatin tablet is effective in the treatment of extremely high-risk ASCVD, significantly improving the total effective rate and the early and sustained LDL-C target attainment rate, and more effectively reducing LDL-C levels and stabilizing plaques. The mechanism may be related to significantly inhibiting PCSK9 levels and further enhancing lipid-lowering and plaque-stabilizing effects.

To investigate the clinical efficacy and safety of budesonide/formoterol/glycopyrronium inhalation aerosol combined with bacterial lysate capsules in the treatment of patients with moderate-to-severe stable chronic obstructive pulmonary disease (COPD) complicated with bronchiectasis.

The patients with moderate-to-severe stable COPD complicated with bronchiectasis admitted to our hospital were divided into control group and treatment group based on their treatment regimens. Patients in control group were administered budesonide/formoterol/glycopyrronium inhalation aerosol (1 inhalation per time, twice daily), while treatment group additionally received oral bacterial lysate capsules (7 mg once daily on an empty stomach, 10 consecutive days followed by a 20-day break as one cycle). Patients in both groups were treated for 6 months. Differences in clinical efficacy, acute exacerbation, airway inflammation indicators, immune function indicators and pulmonary function were compared, and safety evaluation was performed.

A total of 116 participants were enrolled, with 57 cases in control group and 59 cases in treatment group. The treatment group achieved an overall effective rate of 91.53% (54 cases/59 cases), which was statistically significantly higher to 77.19% (44 cases/57 cases) observed in control group(P<0.05). After treatment, the number of acute exacerbations in treatment and control group were (1.53±0.50) and (1.74±0.48) episodes, respectively; the duration of acute exacerbations were (9.80±2.75) and (11.16±3.06) days, respectively; the soluble triggering receptor expressed on myeloid cells-1 (sTREM-1) levels were (33.89±7.47) and (38.34±8.35) pg·mL^-1, respectively; the endothelin (ET) levels were (27.75±4.68) and (30.25±6.12) pg·mL^-1, respectively; the soluble urokinase-type plasminogen activator receptor (suPAR) levels were (244.01±44.13) and (264.13±52.27) pg·mL^-1, respectively; the immunoglobulin (Ig) A levels were (2.97±0.51) and (2.75±0.52) g·L^-1, respectively; the IgG levels were (12.05±2.55) and (10.89±2.34) g·L^-1, respectively; the IgM levels were (1.95±0.40) and (1.76±0.32) g·L^-1, respectively; the IgE levels were (87.67±10.26) and (93.61±13.58) IU·mL^-1, respectively; the diffusing capacity for carbon monoxide (DLCO) were (67.80±8.43)% and (64.38±7.81)%, respectively; the residual volume/total lung capacity ratio (RV/TLC) were (41.57±4.25)% and (43.61±4.11)%, respectively; the maximum minute ventilation during exercise (VE_max) were (54.24±5.61) and (51.96±5.58) L·min^-1, respectively. Intergroup comparisons revealed statistically significant differences in the aforementioned indicators (P<0.05, P<0.01). Adverse drug reactions in treatment group included nausea, dizziness, mild elevated transaminase, dry mouth and hoarseness; those in control group included nausea and retching, rash, pharyngeal discomfort and elevated bilirubin. The total incidence of adverse reactions in treatment group and control group were 11.86% (7 cases/59 cases) and 8.77% (5 cases/57 cases), respectively, with no statistically significant difference (P>0.05).

Budesonide/formoterol/glycopyrronium inhalation aerosol combined with bacterial lysate capsules can reduce the risk of acute exacerbations and effectively improve pulmonary function in patients with moderate-to-severe stable COPD complicated with bronchiectasis. The underlying mechanism may be associated with the alleviation of airway inflammation and the enhancement of immune function

To explore the potential mechanism of rosmarinic acid in reducing sepsis related kidney injury.

In the animal experiment, BALB/c mice were randomly divided into animal control group, animal model group [10 mg·kg^-1 lipopolysaccharide (LPS) modeling], animal low-dose experimental group (modeling+10 mg·kg^-1 rosmarinic acid) and animal high-dose experimental group (modeling+20 mg·kg^-1 rosmarinic acid), with 10 mice in each group. In the cell experiment part, RAW264.7 cells were randomly divided into cell blank group, cell model group (1 μg·mL^-1 LPS), cell low-dose experimental group (modeling+20.00 μmol·mL^-1 rosmarinic acid) and cell high-dose experimental group (modeling+40.00 μmol·mL^-1 rosmarinic acid). Serum and renal tissue inflammatory related indicators were analyzed by enzyme linked immunosorbent assay (ELISA) kit and real-time fluorescent quantitative polymerase chain reaction (RT-qPCR). Renal tissue differentiation cluster 86 (CD86)⁺cells and F4/80⁺cells were co-located by immunohistochemistry.

In the animal experiment part, the serum creatinine (Scr) levels of animal control group, animal model group, low-dose experimental group and high-dose experimental group were (14.80±0.73), (59.73±6.79), (50.06±5.12) and (43.62±3.73) mmol·L^-1, respectively; the levels of inducible nitric oxide synthase (iNOS) were (1.26±0.11), (4.74±0.11), (3.86±0.23) and (2.48±0.28) U·L^-1, respectively; the levels of tumor necrosis factor-alpha (TNF-α) were (14.00±1.47), (85.90±6.66), (64.97±5.62) and (46.84±1.95) pg·mL^-1, respectively; the levels of interleukin (IL)-6 were (6.93±0.47), (50.05±3.84), (39.93±3.50) and (27.26±2.09) pg·mL^-1, respectively; the levels of IL-1 β were (22.17±2.27), (122.42±12.77), (91.54±6.84) and (61.23±6.31) pg·mL^-1, respectively; the CD86⁺/F4/80⁺ co-located cells were (100.00±4.85)%, (476.99±39.89)%, (322.15±24.15)% and (219.90±19.81)%, respectively. There were statistically significant differences in the above indexes between animal model and animal control group, between low-dose, high-dose experimental groups and animal model group, and between high-dose experimental group and low-dose experimental group (P<0.05, P<0.01, P<0.001). In the cell experiment, the relative expression levels of iNOS mRNA in the cell blank group, cell model group, cell low-dose experimental group and cell high-dose experimental group were 1.00±0.10, 3.26±0.31, 2.51±0.27 and 1.94±0.19, respectively; the relative expression levels of TNF - α mRNA were 1.00±0.14, 2.54±0.26, 2.07±0.22 and 1.77±0.18, respectively; the relative expression levels of IL-1β mRNA were 1.00±0.12, 2.24±0.30, 1.83±0.22 and 1.52±0.17, respectively; the relative expression levels of IL-6 mRNA were 1.00±0.08, 2.43±0.17, 1.85±0.21 and 1.54±0.16, respectively. There were statistically significant differences in the above indexes between cell model group and cell blank group, between low-dose and high-dose experimental groups and cell model group, and between high-dose experimental group and low-dose experimental group (P<0.01, P<0.001).

Rosmarinic acid plays a protective role in LPS-induced acute kidney injury by inhibit macrophage activation and inhibition of their transformation into M1-type macrophages.

To observe the clinical efficacy and safety of low molecular weight heparin (LMWH) calcium injection combined with cimetidine (CIM) injection in the treatment of children with recurrent Henoch-Schönlein purpura (HSP).

Children with recurrent HSP were randomly divided into control group and treatment group. Both groups received conventional comprehensive treatment. The control group was administered 10 mg·kg^-1 of CIM injection for intravenous infusion, bid. The treatment group received subcutaneous injection of 100 IU·kg^-1 LMWH calcium injection in addition to control group’s regimen, qd. Both groups underwent continuous treatment for 14 days. Clinical efficacy, renal injury indicators, coagulation function parameters, immunoglobulin levels, T lymphocyte counts and inflammatory response markers were compared between the two groups, along with safety evaluation.

This clinical trial enrolled a total of 92 pediatric patients, with 46 cases each group. After treatment, the overall response rates were 78.26% (36 case/46 case) in control group and 93.48% (43 case /46 case) in treatment group; the urinary microalbumin (mALB) levels were (26.43±2.37) and (25.31±1.82) mg·L^-1, respectively; urinary α1-microglobulin (α1-MG) levels were (10.23±1.22) and (9.58±1.25) mg·L^-1, respectively; N-acetyl-β-D-glucosaminidase (NAG) levels were (16.32±1.12) and (15.70±1.18) U·L^-1, respectively; cystatin C (CysC) levels were (0.77±0.19) and (0.69±0.13) mg·L^-1, respectively; plasma D-dimer (D-Dimer) levels were (167.49±25.27) and (157.35±22.80) ng·mL^-1, respectively; fibrinogen (FIB) levels were (3.19±0.87) and (2.81±0.48) g·L^-1, respectively; prothrombin time (PT) were (11.44±1.19) and (12.17±1.52) s, respectively; the activated partial thromboplastin time (APTT) were (28.76±4.49) and (30.90±3.62) s, respectively; immunoglobulin A (IgA) levels were (2.35±0.56) and (2.08±0.59) g·L^-1, respectively; IgE levels were (74.74±9.64) and (71.04±7.78) IU·L^-1, respectively; IgG levels were (10.61±1.77) and (10.63±1.61) g·L^-1, respectively; IgM levels were (1.31±0.28) and (1.29±0.26) g·L^-1, respectively; CD4-positive T lymphocyte (CD4⁺) percentage were (37.89±4.92)% and (40.86±6.02)%, respectively; CD8⁺ percentage were (26.22±3.28)% and (24.55±3.01)%, respectively; CD4⁺/CD8⁺ ratio were 1.54±0.50 and 1.77±0.55, respectively; interferon-γ (IFN-γ) levels were (15.33±3.81) and (13.48±3.60) pg·mL^-1, respectively; interleukin-4 (IL-4) levels were (27.38±4.07) and (25.33±3.47) pg·mL^-1, respectively; interleukin-17 (IL-17) levels were (80.98±8.12) and (76.60±8.06) ng·L^-1, respectively. All these parameters in treatment group showed statistically significant differences compared to control group (P<0.05, P<0.01). The main adverse drug reactions in treatment group included injection site redness and swelling, fatigue and vomiting, while those in control group included nausea, dizziness and vomiting. The overall incidence of adverse drug reactions was 6.52% (3 cases/46 cases) in control group and 8.70% (4 cases/46 cases) in treatment group, with no statistically significant difference between the two groups (P>0.05).

The combination of LMWH calcium injections and CIM injections demonstrates superior efficacy in treating recurrent HSP in children, alleviating immune stress, exerting anti-inflammatory effects, and exhibiting safety profiles.

To observe the clinical efficacy of short-term intensive insulin therapy combined with blood purification in the treatment of hypertriglyceridemic severe acute pancreatitis (HTG-SAP).

HTG-SAP patients were divided into control group and treatment group based on the treatment method. The control group received continuous blood purification (CBP) treatment for 24 to 48 hours, and the next treatment was performed after a 24-hour interval for a total of 2 treatments. The treatment group received continuous intravenous pumping of CBP combined with 0.1-0.3 U·kg^-1·h^-1 insulin injection. The course of treatment in both groups was 7 days. The clinical efficacy, clinical symptom relief time, prognostic indicators, clinical scores, blood lipid levels, inflammation and biochemical factor levels were compared between the two groups, and safety was evaluated.

A total of 78 patients were enrolled, with 41 cases in control group and 37 cases in treatment group. The total effective rates of treatment in the treatment group and the control group were 89.19% (33 cases/37 cases) and 70.73% (29 cases/41 cases), respectively, with statistical significance differences between the two groups (P<0.05). After treatment, the disappearance times of abdominal distension in the treatment and control groups were (6.27±1.10) and (6.93±1.27) days, respectively; the disappearance times of abdominal pain were (4.97±0.80) and (5.46±1.10) days, respectively; the recovery times of bowel sounds were (3.14±0.63) and (3.56±0.71) days, respectively; the first defecation times were (4.08±0.86) and (4.66±1.33) days, respectively; the total hospitalization times were (17.78±3.29) and (19.54±4.15) days, respectively. the recovery times of organ failure were (6.32±1.62) and (7.24±2.13) days, respectively; the incidences of local complications were 8.11% (3 cases/37 cases) and 26.83% (11 cases/41 cases), respectively; the incidences of systemic complications were 10.81% (4 cases/37 cases) and 29.27% (12 cases/41 cases), respectively; the Bedside Index for Severity in Acute Pancreatitis (BISAP) scores were (1.51±0.51) and (1.83±0.38) points, respectively; the Acute physiology and chronic health evaluation scoring system (APACHE II) scores were (6.05±1.13) points and (6.88±1.44) points, respectively; triglyceride (TG) levels were (4.63±1.07) mmol·L^-1 and (5.41±1.26) mmol·L^-1, respectively; total cholesterol (TC) were (4.95±1.01) and (5.73±1.27) mmol·L^-1, respectively; low-density lipoprotein cholesterol (LDL-C) were (2.87±0.43) and (3.15±0.56) mmol·L^-1, respectively; serum amylase (AMY) levels were (138.46±25.49) and (159.85±33.43) U·L^-1, respectively; interleukin-8 (IL-8) levels were (28.65±5.15) and (32.18±6.42) pg·mL^-1, respectively; C-reactive protein (CRP) levels were (29.88±4.81) and (33.12±6.01) mg·L^-1, respectively; the differences of above indexes were all statistically significant (all P<0.05). The incidence of drug adverse reactions of the treatment group and the control group were 5.41% (2 cases/37 cases) and 2.44% (1 case/41 cases), respectively and there was no statistical significance between the two groups (P>0.05).

Short-term intensive insulin therapy combined with blood purification can effectively improve the clinical efficacy of HTG-SAP patients, significantly improve clinical symptoms, organ function recovery, clinical scores, blood lipids, inflammation and biochemical indicators, and does not increase the risk of adverse reactions, which has clinical application value.

To observe the clinical efficacy and safety of azelastine hydrochloride eye drops combined with polyvinyl alcohol eye drops in the treatment of allergic conjunctivitis in children aged 4-6 years.

Children with allergic conjunctivitis were divided into control group and treatment group based on the medication regimen. The control group received azelastine hydrochloride eye drops,1 drop each time, tid; while the treatment group received additional polyvinyl alcohol eye drops, 1 drop each time, tid. The treatment duration was 2 weeks. The two groups were compared in terms of clinical efficacy, comprehensive ocular symptom scores, tear film stability indicators, inflammatory factor levels, tear meniscus parameters and the incidence of adverse drug reactions were eveluated.

A total of 99 children were enrolled, including 48 cases in the control group and 51 cases in the treatment group. After treatment, the total effective rates in the treatment group and control group were 92.16% (47 cases/51 cases) and 89.58% (43 cases/48 cases), respectively, with no statistically significant difference between the two groups (P>0.05). After treatment, the scores for eye itching of the treatment group and the control group were (0.65±0.56) and (0.92±0.45) points, respectively; scores for foreign body sensation were (0.35±0.56) and (0.65±0.56) points, respectively; scores for tearing were (0.35±0.52) and (0.65±0.53) points, respectively; scores for photophobia were (0.37±0.49) and (0.63±0.57) points, respectively; the levels of hyaluronic acid (HA) were (85.58±9.36) and (90.69±10.58) μg·L^-1, respectively; the levels of eosinophil cationic protein (ECP) were (6.36±0.89) and (6.82±0.95) μg·L^-1, respectively; the levels of thymic stromal lymphopoietin (TSLP) were (7.57±1.59) and (8.43±1.48) pg·mL^-1, respectively; the tear film breakup time (TBUT) were (11.49±1.37) and (10.83±1.19) s, respectively; the corneal fluorescein staining (CFS) score were (1.93±0.55) and (2.17±0.41) points, respectively; the lipid layer thickness (LLT) were (58.46±5.84) and (55.52±5.63) nm, respectively; the incomplete blink ratio (PBR) were (56.49±5.21) and (58.95±5.71)%, respectively; the meibomian gland dropout rate (MGDR) of the upper eyelids were (14.49±2.06)% and (15.36±1.88)%, respectively; MGDR of lower eyelids were (21.25±3.07)% and (22.87±2.79)%, respectively; the tear meniscus depth (TMD) were (219.64±24.56) and (208.65±23.57) μm, respectively; tear meniscus height (TMH) were (237.61±26.82) and (223.49±27.48)μm, respectively; tear meniscus area (TMA) were (58.49±8.33) and (55.07±8.11) μm², respectively. For all the above parameters, the differences between the two groups were all statistically significant (all P<0.05). The total incidence of adverse drug reactions in the treatment group and control group was 5.88% (3 cases/51 cases) and 8.33% (4 cases/48 cases), respectively, with no statistically significant difference (P>0.05).

The combination of azelastine hydrochloride eye drops and polyvinyl alcohol eye drops demonstrates good efficacy in treating allergic conjunctivitis in children aged 4-6 years, significantly improving ocular symptoms and tear film stability, reducing inflammatory markers, and without increasing adverse drug reactions.